Company / Cost of Revenue
Immunocore Holdings plc Cost of Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$5.1M
FY2025
5-year range
$0 / $5.1M
FY2021-FY2025
Trend
+86.3%
vs FY2024
Sector context
#75 of 85
Health Care
What the data says
Immunocore Holdings plc's cost of revenue of $5M is lower than 88% of companies in the Health Care sector (FY2025). Increased from $1M to $5M over the past 2 years.
Based on SEC 10-K filings.
$5M in FY2025 with a 3-year CAGR of +67.2%.
Increased from $1M to $5M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +67.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 85This company $5.1M Sector average $2.0B
▼
-99.7% below sector average
Key checks
Key Insights
- 3-year CAGR of +67.2%, indicating consistent growth.
- In FY2025, cost of revenue increased 86.3% year-over-year.
- Ranks #75 out of 85 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.1M | +86.3% |
| FY2024 | $2.7M | +163.4% |
| FY2023 | $1.0M | -4.8% |
| FY2022 | $1.1M | - |
| FY2021 | $0 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026